Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies

• Autori principali: Richard Burt (Autore), Dana Warcel (Autore), Adele K. Fielding (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2019-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient's T cells with CD19-expressing tumour cells. Clinical trials have demo...